Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion.
Article in JCO precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Maria FattehDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Jaime WehrDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Katerina KaraindrouDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Rena R XianThe Johns Hopkins Molecular Tumor Board, Johns Hopkins University School of Medicine, Baltimore, MD.
Christopher GockeThe Johns Hopkins Molecular Tumor Board, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0002-9541-2192
Ming-Tseh LinThe Johns Hopkins Molecular Tumor Board, Johns Hopkins University School of Medicine, Baltimore, MD.
Dana PetryDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Kala VisvanathanDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0002-0582-8005
Rima CouziDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Cesar Santa MariaDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0003-0979-8787
Vered StearnsDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0003-4018-4708
Jessica J TaoDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0002-6532-4466
Valsamo AnagnostouDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0001-9480-3047
Jenna V CanzonieroDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0003-1084-6918
and the Johns Hopkins Molecular Tumor Board
Johns Hopkins Molecular Tumor Board
Funding
Matching genotypes with personalized therapies: Development of a decision support infrastructure to augment the value of precision medicineU01CA274631 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANAGNOSTOU, VALSAMO, BOTSIS, TAXIARCHIS · 2023 to 2025
$1.2M
NCI NIH HHS U01 CA274631
6 · The paper itself
Abstract
Polyclonal convergent evolution to PARPi resistance in a patient with metastatic breast cancer with gPALB2.
Indexed as
Breast NeoplasmsDrug Resistance, NeoplasmMutationPoly(ADP-ribose) Polymerase InhibitorsFemaleHumansPoly(ADP-ribose) Polymerase Inhibitors
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion. · full record | OpenQuestion